When the primary driver of fatal overdoses began transitioning from prescription painkillers to heroin around 2012, researchers were tasked with discovering safer alternatives for pain relief. In 2017, backed by funding from the National Institute on Drug Abuse, a team of scientists reported in the journal Cell that multiple synthetic compounds held promise. Among them was SR-17018, a substance capable of delivering pain relief in mice without triggering respiratory depression, the physiological failure to breathe that typically causes opioid-related deaths.
From Laboratory Trials to Online Communities
Laura Bohn, senior associate vice president of research at University of South Florida Health, led the team that filed a patent on SR-17018. Subsequent laboratory experiments demonstrated that mice administering the compound did not build a significant tolerance. Furthermore, animals already dependent on morphine, a potent opioid analgesic, were able to use SR-17018 to reset their physiological tolerance without suffering from agonizing withdrawal symptoms.
The application of SR-17018 eventually extended beyond animal models. On digital discussion platforms such as Reddit and Discord, individuals struggling with substance dependency began discussing the chemical as a uniquely effective tool for breaking their addiction to various opioids. Because it had not been designated as a federally controlled substance, the unapproved compound remained relatively accessible online. Concurrently, Laura Bohn was preparing to organize the very first human clinical trials to examine its safety and efficacy under medical supervision.
The DEA Schedule I Action and Research Obstacles
The trajectory of the research and its online use altered abruptly in late August when the US Drug Enforcement Administration utilized its emergency scheduling authority to place SR-17018 into Schedule I. This restrictive regulatory tier, shared with illicit drugs like heroin, is reserved for substances deemed to have a high abuse liability and no accepted medical value.
The regulatory classification imposes immediate administrative barriers on academic laboratories. Laura Bohn noted that ongoing safety investigations have ground to a halt because researchers are prohibited from manufacturing, handling, or transporting the substance without extensive Schedule I licensing. For people seeking to break their physical dependence outside medical supervision, the ban eliminated an unapproved yet widely sought alternative, despite the absence of formal clinical data in humans.
Personal Accounts of Tapering and Withdrawal Relief
Jim Bates, a 53-year-old kitchen manager living in Duncan, Oklahoma, had struggled with various substances, including prescription narcotics, heroin, and fentanyl, since age 25. Approximately two years ago, he developed an addiction to 7-OH, a potent alkaloid found in kratom that stimulates opioid receptors in the brain, after buying it at a vape shop. He described the intensity of the substance as being very similar to heroin.
He later switched to MGM-15, another compound that provided an experience comparable to oxycodone. Both 7-OH and MGM-15 were placed into Schedule I by the DEA earlier during the summer. As his dependence deepened, Jim Bates spent months searching Discord and Telegram communities for strategies to detoxify. Roughly 11 months ago, he obtained SR-17018 and used it over three weeks to completely taper off MGM-15.
Unlike previous attempts to discontinue 7-OH, which resulted in intense anxiety and restless legs syndrome, Jim Bates experienced no physical withdrawal symptoms and noted that the compound produced no euphoric high. Another individual, Michael, who withheld his surname for privacy, similarly turned to SR-17018 in January after at least five failed attempts to quit 7-OH. Each previous attempt had involved days of severe illness followed by an extended depressive state. Michael reported that while the chemical did not eliminate every single negative effect, it alleviated his sweating, restlessness, and anxiety sufficiently to allow him to continue working without disrupting his daily routine.
Both men had previously received established medical therapies such as buprenorphine and methadone. However, they expressed a clear preference for SR-17018 because it did not require indefinite daily maintenance, which itself produces protracted withdrawal upon cessation. Michael suggested that regulatory pushback stemmed in part from the compound's potential to disrupt commercial maintenance medication markets that keep patients reliant on long-term treatments.
Administrative Rationale and Legal Pushback
Prior to the official order, Denver-based attorney Robert Rush submitted a formal petition urging the DEA to reconsider its emergency scheduling. Robert Rush, who serves as the executive director of the nonprofit Rights and Reason Project and represents Laura Bohn in legal matters, argued that SR-17018 presents a markedly lower risk profile than typical illicit synthetic narcotics. The regulatory agency did not issue a direct response to his filing.
In its official notice of intent, the DEA explained its decision to classify SR-17018 alongside three other synthetic opioids. The document highlighted that the National Forensic Laboratory Information System, which monitors substances seized by law enforcement, had identified two samples of SR-17018 across two US states since 2025. Additionally, the Rapid Drug Analysis and Research monitoring framework had detected trace occurrences in the West Coast region.
The DEA maintained that the four synthetic substances lack recognized therapeutic applications and pose trafficking and abuse hazards comparable to standard synthetic opioids based on forensic toxicological exhibits. The agency also noted that because the compound resets physiological opioid tolerance, an individual who returns to active drug use might face an elevated risk of accidental overdose, an outcome that equally occurs following traditional abstinence.
Implications for Future Dependency Therapies
Robert Rush criticized the emergency regulatory action as disproportionate, emphasizing that the compound has not been linked to emergency medical admissions or documented fatalities. Emergency scheduling remains active for an initial two-year duration with the option for a one-year extension, during which time the agency may seek permanent Schedule I classification through public and scientific proceedings.
A critical feature of the temporary emergency procedure is that it precludes judicial review during the initial enforcement phase. Robert Rush warned that eliminating unregulated retail opioids while simultaneously banning potentially restorative compounds risks exacerbating broader public health challenges. Halting scientific progress on an agent that could underpin next-generation treatments for chemical dependency, he argued, removes a valuable pathway toward solving the chronic addiction crisis.
